focus -WSS

focus

author：Wikipedia 2025-09-29 18:17:59 - browse：5

Golden brain and DNA spiral illustration. -- biotech coverage from STAT — Adobe

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.

Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and sovereign wealth fund Alaska Permanent Fund Corp. The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year.

Kenai — pronounced key-nigh — is developing therapies that use induced pluripotent stem cells, or iPSCs. These highly versatile organisms are derived from skin or blood cells and can be transformed into any type of cell. In Parkinson’s, the idea is that these cells would replace damaged neurons.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： What to expect at HLTH 2023, the health care industry conference

WSS

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Teacher posts viral 'school supply rant' with advice for parents

Physician executives need more than on

A virus, fished out of a lake, may have saved a man’s life

Poland's lawmakers approve a divisive law on Russian influence

Why age limits for politicians are a terrible idea

explore

focus

knowledge

Cancer drug shortages should be causing more outrage

American TikTok star stuck in Dubai for months following rental car altercation

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA panel signals lack of confidence in Amgen cancer drug data

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Histogen: Failed biotech offers rare public look inside

Activists slam private health insurers over coverage restrictions

Snowpack in the West is melting rapidly. Where will all that extra water go?

Malaria cases in Florida and Texas: Here’s what you need to know

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

explore

House GOP plan to stem drug shortages differs from Democrats’

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

What AstraZeneca

Was Amgen transparent enough on FDA's concern on cancer drug?

A virus, fished out of a lake, may have saved a man’s life

Liquid biopsy for lung cancer is launched by Delfi

focus

focus

focus

focus